Historically, use of PI3K pathway inhibitors in cancer therapy has applied mainly to patients with advanced cancers and limited life expectancy, hence strategies to reduce side effects focused more on short-term rather than long-term complications, with an acceptance of some degree of toxicity in the short term in the interest of extending life [58]. Here, PIK3CA is linked to cancer.